Sulfadiazine
Head and Neck Carcinoma
OHSU Knight Cancer InstituteSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
43 Active assets in the Head and Neck Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | BB |
Pembrolizumab National Cancer Institute (NCI) | Phase 2 | BB |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Tadalafil University of California, San Diego | Phase 2 | B |
Binimetinib National Cancer Institute (NCI) | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
Sulfadiazine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →